Azitra Inc(AZTR) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
September 30 at 7:48 PM ET (Korea 10/1 08:48)
Full metrics table
| Index | - | P/E | - | EPS (ttm) | -1.31 | Insider Own | 6.71% | Shs Outstand | 60.6M | Perf Week | -16.86% |
| Market Cap | 0.01B | Forward P/E | - | EPS next Y | 70% | Insider Trans | - | Shs Float | 56.5M | Perf Month | -21.37% |
| Enterprise Value | 0.00B | PEG | - | EPS next Q | -0.02 | Inst Own | 32.04% | Short Float | 1.24% | Perf Quarter | -17.41% |
| Income | -0.01B | P/S | - | EPS this Y | 91.11% | Inst Trans | 38.36% | Short Ratio | 0.39 | Perf Half Y | -41.2% |
| Sales | 0.00B | P/B | 1.14 | EPS next 5Y | 70.12% | ROA | -190.69% | Short Interest | 0.70M | Perf YTD | -48.04% |
| Book/sh | 0.12 | P/C | 1.24 | EPS past 3/5Y | 78.38% 67.17% | ROE | -256.67% | 52W High | -87.38% ($1.09) | Perf Year | -80.31% |
| Cash/sh | 0.11 | P/FCF | - | Sales past 3/5Y | - | ROIC | -166.18% | 52W Low | 37.6% ($0.10) | Perf 3Y | -99.95% |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | 78.16% | Gross Margin | - | Volatility(W/M) | 11.73% 7.76% | Perf 5Y | - |
| Dividend TTM | - | EV/Sales | - | Sales Y/Y TTM | -100% | Oper. Margin | - | ATR (14) | 0.01 | Perf 10Y | - |
| Dividend Ex-Date | - | Quick Ratio | 4.86 | EPS Q/Q | 85.33% | Profit Margin | - | RSI (14) | 36.27 | Recom | 1 |
| Dividend Gr. 3/5Y | - | Current Ratio | 4.86 | Sales Q/Q | - | SMA20 | -18.8% ($0.17) | Beta | -1.03 | Target Price | $0.34 |
| Payout | - | Debt/Eq | 0.06 | Earnings | 2026/8/12 | SMA50 | -9.94% ($0.16) | Rel Volume | 0.32 | Prev Close | $0.13 |
| Employees | 13 | LT Debt/Eq | 0.01 | EPS/Sales Surpr. | -47.83% - | SMA200 | -32.67% ($0.21) | Avg Volume(3M) | 1.78M | Price | $0.14 |
| IPO | 2023/6/16 | Option/Short | No/Yes | Trades | 431 | Volume | 573,839 | Change | 5.36% |
🧫 Azitra is a clinical-stage precision dermatology biotech company headquartered in Branford, Connecticut. The company develops live biotherapeutic products (LBPs) using genetically engineered *Staphylococcus epidermidis* to target rare skin diseases such as Netherton syndrome, as well as rash-related side effects of cancer therapies.
Over the past 1 year, on the lower side
87% below its 1-year high.
Traded less than usual That is 32% of its average volume.
AZTR has a sound balance sheet but weak earning power
Losses or thin margins. Early-stage growth or weakening competitiveness
Tap to view numbers
Earnings are growing steadily
Earnings are expected to grow by +91.1% this year.
Tap to view numbers
Results came in about as expected
Mixed beats and misses
Tap to view numbers
Opinions on the outlook are split
Analyst sentiment is Strong Buy.
Tap to view numbers
Holding long would have lost money
Bought 3 years ago, your return today would be -100.0%.
Tap to view numbers
No dividend
There is no profit to distribute yet.
Ownership looks stable
Institutions hold 32.0%.
Tap to view numbers
It ranks #524 of 592 in the industry
Based on market cap of $8M.
FAQ
What kind of company is AZTR?
AZTR belongs to the Healthcare sector and operates in the Biotechnology industry.
What is the market cap of AZTR?
The market cap of AZTR is approximately $8M, ranking 5,544 within its sector.
What is the 52-week high and low for AZTR?
AZTR has recorded a 52-week high of $1.09 and a low of $0.10.
